文献速递消化系统肿瘤

瑞戈非尼联合伊匹木单抗和纳武利尤单抗治疗微卫星稳定结直肠癌化疗后进展患者的1期非随机临床试验

Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项单中心3+3剂量递减1期非随机试验纳入39例标准化疗后进展、未接受过瑞戈非尼或抗PD-1治疗的微卫星稳定转移性结直肠癌患者,确定瑞戈非尼80 mg/d联合伊匹木单抗1 mg/kg每6周和纳武利尤单抗240 mg每2周为推荐2期剂量,该剂量组客观缓解率27.6%,中位无进展生存期4个月,中位总生存期20个月。

要点

  • 推荐2期剂量为瑞戈非尼80 mg/d联合伊匹木单抗1 mg/kg每6周和纳武利尤单抗240 mg每2周。
  • 推荐2期剂量组客观缓解率27.6%,中位无进展生存期4个月,中位总生存期20个月。
  • 无肝转移患者客观缓解率36.4%,中位无进展生存期5个月,中位总生存期大于22个月。

核心结论

  • 作者认为,推荐2期剂量的瑞戈非尼联合伊匹木单抗和纳武利尤单抗在无肝转移的晚期微卫星稳定结直肠癌患者中显示出有意义的临床活性。
  • 作者指出这些发现应在随机临床试验中确认。

研究设计与样本

  • 单中心3+3剂量递减1期非随机临床试验,附推荐2期剂量有效性扩展队列。
  • 2020年5月12日至2022年1月21日入组39例标准化疗后进展、未接受过瑞戈非尼或抗PD-1治疗的微卫星稳定转移性结直肠癌患者。
  • 患者接受瑞戈非尼每日口服连用21天每4周重复,伊匹木单抗1 mg/kg静脉每6周固定剂量,纳武利尤单抗240 mg静脉每2周固定剂量,治疗至进展、不可接受毒性或完成2年治疗。

主要发现

  • 起始剂量瑞戈非尼80 mg/d的前9例患者未观察到剂量限制性毒性,无需剂量递减,该剂量被确定为推荐2期剂量。
  • 推荐2期剂量队列客观缓解率27.6%,中位无进展生存期4个月(四分位距2-9个月),中位总生存期20个月(四分位距7个月至不可估计)。
  • 22例无肝转移患者客观缓解率36.4%,中位无进展生存期5个月(四分位距2-11个月),中位总生存期大于22个月。
  • 剂量优化队列第1周期瑞戈非尼40 mg/d、第2周期起80 mg/d,皮肤和免疫毒性较低,但活性有限,10例中5例最佳缓解为疾病稳定。

关键数值与推荐

  • 推荐2期剂量:瑞戈非尼80 mg/d每日口服连用21天每4周重复,伊匹木单抗1 mg/kg静脉每6周,纳武利尤单抗240 mg静脉每2周。
  • 推荐2期剂量队列客观缓解率27.6%,中位无进展生存期4个月(四分位距2-9个月),中位总生存期20个月(四分位距7个月至不可估计)。
  • 无肝转移患者(22例)客观缓解率36.4%,中位无进展生存期5个月(四分位距2-11个月),中位总生存期大于22个月。

临床怎么用

  • 作者认为推荐2期剂量的瑞戈非尼联合伊匹木单抗和纳武利尤单抗在无肝转移的晚期微卫星稳定结直肠癌患者中显示出有意义的临床活性。
  • 作者指出这些发现应在随机临床试验中确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immunotherapy combinations with activity in patients with microsatellite stable (MSS) metastatic colorectal cancer need to be identified. OBJECTIVE: To determine the recommended phase 2 dose (RP2D) of regorafenib, ipilimumab, and nivolumab (RIN) and evaluate its activity in an expansion cohort of patients with MSS metastatic colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial was a single-center 3 + 3 dose de-escalation study with an effectiveness expansion cohort at the RP2D. After the identification of the RP2D, a study amendment was executed to explore a regorafenib dose optimization strategy to mitigate skin-related toxic effects. Study enrollment occurred between May 12, 2020, and January 21, 2022. The trial was conducted at a single academic center. A total of 39 patients with MSS metastatic colorectal cancer whose disease progressed after standard chemotherapy and who had not received prior regorafenib or anti-programmed cell death protein 1 therapy were included. INTERVENTIONS: Patients received regorafenib daily for 21 days every 4 weeks; fixed-dose ipilimumab, 1 mg/kg, intravenously every 6 weeks; and fixed-dose nivolumab, 240 mg intravenously every 2 weeks. Patients were treated until progression, unacceptable toxic effects, or completion of 2 years of therapy. MAIN OUTCOMES AND MEASURES: The primary end point was RP2D selection. Secondary end points were safety and overall response rate (ORR) according to the Response Evaluation Criteria in Solid Tumours at the RP2D level. RESULTS: A total of 39 patients were enrolled, 23 (59.0%) were female, median age was 54 years (range, 25-75 years), 3 were Black (7.7%), and 26 were White (66.7%). No dose-limiting toxic effects were noted in the first 9 patients at the starting dose of RIN, with regorafenib dosed at 80 mg daily. No dose de-escalation was needed. This dose was declared the RP2D. Twenty more patients were enrolled at this level. The ORR, median progression-free survival (PFS), and overall survival (OS) in the RP2D cohort were 27.6%, 4 months (IQR, 2-9 months), and 20 months (IQR, 7 months to not estimable), respectively. For the 22 patients without liver metastases, the ORR, PFS, and OS were 36.4%, 5 months (IQR, 2-11), and greater than 22 months, respectively. A dose optimization cohort with regorafenib at 40 mg/d on cycle 1 and 80 mg/d on cycle 2 and beyond was associated with lower skin and immune toxic effects but had limited activity with stable disease for 5 of 10 patients as the best response. CONCLUSIONS AND RELEVANCE: Results of this nonrandomized clinical trial suggest that RIN at the RP2D demonstrated interesting clinical activity in patients with advanced MSS colorectal cancer without liver metastases. These findings should be confirmed in randomized clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04362839.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Fakih M, Sandhu J, Lim D, et al. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2023. PMID: 36892833. doi:10.1001/jamaoncol.2022.7845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。